Data from the phase 2 the phase 3 SWOG S1216 presented during the ASCO Annual Meeting shows numerical overall survival improvement with he experimental combination that missed the threshold for statistical significance.
Immunotherapies are now accepted treatments in the maintenance and second-line settings for patients with metastatic urothelial cancer and in the setting of superficial UC–carcinoma in situ with prior intravesical therapy, according to updated NCCN guidelines
Yousef Zakharia, MD, discusses the results of a phase 2 trial investigating concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder.
The FDA has accepted a Biologics License Application for nivolumab for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma and granted it Priority Review.
The FDA’s Oncologic Drug Advisory Committee voted 10 to 1 to continue the accelerated approval of atezolizumab for the frontline treatment of patients with urothelial cancer who are ineligible for cisplatin.